Comparison of Liver Safety of Favipiravir and Hydroxychloroquine in COVID-19 Treatment

Creative Commons License

Izci-Cetinkaya F., Karagoz H., YILDIZ O.

KLIMIK JOURNAL, cilt.33, sa.3, ss.235-240, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/kd.2020.49
  • Dergi Adı: KLIMIK JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Sayfa Sayıları: ss.235-240
  • Erciyes Üniversitesi Adresli: Evet

Özet

Objective: Since the first case from Wuhan, China in December 2019, COVID-19 has spread all over the world and a pandemic was declared by the World Health Organization on January 30, 2020. While there are no specific effective antiviral drugs or vaccines to treat or to prevent COVID-19; favipiravir, hydroxy-chloroquine and their combination are used in the treatment of COVID-19 in Turkey. In this study, it was aimed to evaluate the demographic, clinical and laboratory findings, the treatments given and the effects of treatments on liver tests of the patients followed up with the diagnosis of COVID-19.